Program
dostarlimab
Also written as “Dostarlimab”, “TSR-042” and “Dostarlimab (TSR-042)”.
Its studies are mostly in Ovarian Neoplasms · Endometrial Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Rectal Neoplasms, led by 2 companies.
Drug pageDostarlimab: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 2517 open or running | phase 4since Mar 20, 2025 | Mar 9, 2016 | Nov 23, 2026phase 2 · NCT06567782 |
| AGO Research | 10 open or running | phase 2since Oct 18, 2021 | Oct 18, 2021 | none ahead |
Also a collaborator on its studies: iTeos Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AGO Research only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named dostarlimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, TSR-042
- Oct 18, 2021First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT05126342
TargetBeta
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The one study AGO Research leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05126342Ovarian Neoplasms | 2 | Withdrawn | Nov 1, 2024 | 0 |
How it is read
Names in the registry
- “Dostarlimab”, 22 entries
- “TSR-042”, 2 entries
- “Dostarlimab (TSR-042)”, 1 entry
- “TSR-042 (Dostarlimab)”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 5 studies
- Endometrial Neoplasms, 4 studies
- Neoplasms, 4 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Rectal Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.